Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-too-familiar routine of meetings, deadlines, and the like has returned with a vengeance.
You knew this would happen, yes? To cope, we are relying, as always, on a cuppa stimulation.
Our choice today is old-fashioned vanilla. Feel free to join us.
Remember, no prescription is required. Meanwhile, here are some tidbits to help you along.
Best of luck accomplishing your goals today, and of course, do keep in touch. … Metastatic pancreatic cancer patients who received a targeted pill from Revolution Medicines lived nearly twice as long as patients who received chemotherapy, a striking result in a notoriously deadly and intractable malignancy , STAT reports.
Patients who took the daily pill, called daraxonrasib, lived a median of 13.2 months, compared to 6.7 months for patients who received chemotherapy. The company plans to use the data to apply for approval, although it did not say when.
Revolution received a Commissioner’s National Priority Review Voucher, part of a controversial U.S.
STAT News published a clinical update in Research Highlights on 13 Apr 2026.
The item focuses on STAT+: Pharmalittle: We’re reading about a pancreatic cancer pill, FDA rejecting a Replimune drug again, and more.
Review the original article for the full source wording and details.